• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by Turning Point Therapeutics, Inc. (Amendment)

    4/7/21 4:39:06 PM ET
    $TPTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $TPTX alert in real time by email
    SC 13D/A 1 ss215897_sc13da.htm AMENDMENT NO. 2
     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13D

    Under the Securities Exchange Act of 1934

    (Amendment No. 2)*

     

     

    Turning Point Therapeutics, Inc.

    (Name of Issuer)

                         

    COMMON STOCK

    (Title of Class of Securities)

                       

    90041T108

    (CUSIP Number)

                           

    OrbiMed Advisors LLC

     

    OrbiMed Capital GP VI LLC

     

    OrbiMed Capital LLC

     

    601 Lexington Avenue, 54th Floor

    New York, NY 10022

    Telephone: (212) 739-6400

                           

    (Name, Address and Telephone Number of Person Authorized to
    Receive Notices and Communications)

                           

    March 1, 2021
    (Date of Event which Requires Filing of this Statement)

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.  ☐

     

    Note:  Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits.  See §240.13d-7(b) for other parties to whom copies are to be sent.

     

    * The remainder of this cover page shall be filled out for a Reporting Person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

                  

     
       

     

    CUSIP No.  90041T108    

     

    1

    Names of Reporting Persons.                 

    OrbiMed Advisors LLC

    2

    Check the Appropriate Box if a Member of a Group (See Instructions).

    (a) o

    (b) o

     

     

     

    3

    SEC Use Only  

            

    4

    Source of Funds (See Instructions)

                 

    AF

    5

    Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

                     

    o
    6

    Citizenship or Place of Organization               

    Delaware

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

    7

    Sole Voting Power            

    0

    8

    Shared Voting Power                             

    1,743,950

    9

    Sole Dispositive Power      

    0

    10

    Shared Dispositive Power           

    1,743,950

    11

    Aggregate Amount Beneficially Owned by Each Reporting Person                 

    1,743,950

    12

    Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

                                       

    o
    13

    Percent of Class Represented by Amount in Row (11)                    

    3.6%*

    14

    Type of Reporting Person (See Instructions)                   

    IA

             

     

    * This percentage is calculated based upon 48,979,903 shares of common stock outstanding of Turning Point Therapeutics, Inc. (the “Issuer”), as set forth in the Issuer’s Form 10-K filed with the Securities and Exchange Commission (“SEC”) on March 1, 2021.

     

     

       

     

    CUSIP No. 90041T108    

     

    1

    Names of Reporting Persons.                   

    OrbiMed Capital GP VI LLC

    2

    Check the Appropriate Box if a Member of a Group (See Instructions).

    (a) o

    (b) o

     

     

     

    3 SEC Use Only              
    4

    Source of Funds (See Instructions)           

    AF

    5 Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)            o
    6

    Citizenship or Place of Organization                               

    Delaware

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

    7

    Sole Voting Power           

    0

    8

    Shared Voting Power                

    1,743,950

    9

    Sole Dispositive Power             

    0

    10

    Shared Dispositive Power             

    1,743,950

    11

    Aggregate Amount Beneficially Owned by Each Reporting Person             

    1,743,950

    12 Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)              o
    13

    Percent of Class Represented by Amount in Row (11)             

    3.6%*

    14

    Type of Reporting Person (See Instructions)             

    OO

             

     

    * This percentage is calculated based upon 48,979,903 shares of common stock outstanding of Turning Point Therapeutics, Inc. (the “Issuer”), as set forth in the Issuer’s Form 10-K filed with the Securities and Exchange Commission (“SEC”) on March 1, 2021.

     

     

     

       

     

    CUSIP No. 90041T108    
               
    1

    Names of Reporting Persons.               

    OrbiMed Capital LLC

     
    2

    Check the Appropriate Box if a Member of a Group (See Instructions).

    (a) o

    (b) o

     

     

     

     
    3 SEC Use Only              
    4

    Source of Funds (See Instructions)                 

    AF

     
    5

    Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

                     

    o  
    6

    Citizenship or Place of Organization                    

    Cayman Islands

     

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

    7

    Sole Voting Power            

    617,377

     
    8

    Shared Voting Power           

    0

     
    9

    Sole Dispositive Power             

    617,377

     
    10

    Shared Dispositive Power           

    0

     
    11

    Aggregate Amount Beneficially Owned by Each Reporting Person                 

    617,377

     
    12

    Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

                 

    o  
    13

    Percent of Class Represented by Amount in Row (11)             

    1.3%*

     
    14

    Type of Reporting Person (See Instructions)              

    IA

     
                   

     

    * This percentage is calculated based upon 48,979,903 shares of common stock outstanding of Turning Point Therapeutics, Inc. (the “Issuer”), as set forth in the Issuer’s Form 10-K filed with the Securities and Exchange Commission (“SEC”) on March 1, 2021.

     

     

       

     

    Item 1.  Security and Issuer

     

    This Amendment No. 2 (“Amendment No. 2”) to Schedule 13D (the “Statement”) supplements and amends the Statement on Schedule 13D of OrbiMed Advisors LLC, OrbiMed Capital GP VI LLC, and OrbiMed Capital LLC originally filed with the Securities and Exchange Commission (the “SEC”) on April 24, 2019, as amended by Amendment No. 1 filed with the SEC on May 22, 2020. The Statement relates to the common stock, par value $0.0001 per share (the “Shares”) of Turning Point Therapeutics, Inc., a corporation organized under the laws of Delaware (the “Issuer”), with its principal executive offices located at 10628 Science Center Drive, Suite 225, San Diego, California 92121.  The Shares are listed on the NASDAQ Global Select Market under the ticker symbol “TPTX”. Information given in response to each item shall be deemed incorporated by reference in all other items, as applicable.

     

    This Amendment No. 2 is being filed to report that the beneficial ownership of the outstanding Shares held by the Reporting Persons was reduced by more than 1% since the last filing, and the Reporting Person ceased to own more than 5% of the Shares, following the transactions described in Item 5(c) below.

     

    Item 2.  Identity and Background

     

    (a) This Schedule 13D is being filed by OrbiMed Advisors LLC (“OrbiMed Advisors”), OrbiMed Capital GP VI LLC (“OrbiMed GP”), and OrbiMed Capital LLC (“OrbiMed Capital”) (collectively, the “Reporting Persons”).

     

     (b) — (c), (f) OrbiMed Advisors, a limited liability company organized under the laws of Delaware and a registered investment adviser under the Investment Advisers Act of 1940, as amended, is the managing member of certain entities as more particularly described in Item 6 below.  OrbiMed Advisors has its principal offices at 601 Lexington Avenue, 54th Floor, New York, New York 10022.

     

    OrbiMed GP, a limited liability company organized under the laws of Delaware, is the general partner of a limited partnership as more particularly described in Item 6 below.  OrbiMed GP has its principal offices at 601 Lexington Avenue, 54th Floor, New York, New York 10022.

     

    OrbiMed Capital, a limited liability company organized under the laws of Delaware and a registered investment adviser under the Investment Advisers Act of 1940, as amended, is the investment adviser of certain entities as more particularly described in Item 6 below.  OrbiMed Capital has its principal offices at 601 Lexington Avenue, 54th Floor, New York, New York 10022.

     

    The directors and executive officers of OrbiMed Advisors, OrbiMed Capital, and OrbiMed GP are set forth on Schedules I, II, and III, respectively, attached hereto.  Schedules I, II and III set forth the following information with respect to each such person:

     

    (i)          name;

     

    (ii)         business address;

     

    (iii)        present principal occupation of employment and the name, principal business and address of any corporation or other organization in which such employment is conducted; and

     

    (iv)        citizenship.

     

    (d) — (e) During the last five years, neither the Reporting Persons nor any Person named in Schedules I through IV has been (i) convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors) or (ii) a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

     

       

     

    Item 3.  Source and Amount of Funds or Other Consideration

     

    Not applicable.

     

    Item 4.  Purpose of Transaction

     

    This statement relates to the acquisition of Shares by the Reporting Persons. The Shares acquired by the Reporting Persons were acquired for the purpose of making an investment in the Issuer and not with the intention of acquiring control of the Issuer’s business on behalf of the Reporting Persons’ respective advisory clients.

     

    The Reporting Persons from time to time intend to review their investment in the Issuer on the basis of various factors, including the Issuer’s business, financial condition, results of operations and prospects, general economic and industry conditions, the securities markets in general and those for the Issuer’s Shares in particular, as well as other developments and other investment opportunities.  Based upon such review, the Reporting Persons will take such actions in the future as the Reporting Persons may deem appropriate in light of the circumstances existing from time to time.  If the Reporting Persons believe that further investment in the Issuer is attractive, whether because of the market price of Shares or otherwise, they may acquire Shares or other securities of the Issuer either in the open market or in privately negotiated transactions.  Similarly, depending on market and other factors, the Reporting Persons may determine to dispose of some or all of the Shares currently owned by the Reporting Persons or otherwise acquired by the Reporting Persons either in the open market or in privately negotiated transactions.

     

    Except as set forth in this Schedule 13D, the Reporting Persons have not formulated any plans or proposals which relate to or would result in:  (a) the acquisition by any person of additional securities of the Issuer or the disposition of securities of the Issuer, (b) an extraordinary corporate transaction, such as a merger, reorganization or liquidation, involving the Issuer or any of its subsidiaries, (c) a sale or transfer of a material amount of the assets of the Issuer or any of its subsidiaries, (d) any change in the present Board of Directors or management of the Issuer, including any plans or proposals to change the number or term of directors or to fill any existing vacancies on the board, (e) any material change in the Issuer’s capitalization or dividend policy of the Issuer, (f) any other material change in the Issuer’s business or corporate structure, (g) any change in the Issuer’s charter or bylaws or other instrument corresponding thereto or other action which may impede the acquisition of control of the Issuer by any person, (h) causing a class of the Issuer’s securities to be deregistered or delisted from a national securities exchange or to cease to be authorized to be quoted in an inter-dealer quotation system of a registered national securities association, (i) a class of equity securities of the Issuer becoming eligible for termination of registration pursuant to Section 12(g)(4) of the Act or (j) any action similar to any of those enumerated above.

     

    Item 5.  Interest in Securities of the Issuer

     

     (a) — (b) The following disclosure is based upon 48,979,093 outstanding Shares of the Issuer, as set forth in the Issuer’s Form 10-K filed with the Securities and Exchange Commission on March 1, 2021.

     

    As of the date of this filing, OrbiMed Private Investments VI, LP (“OPI VI”), a limited partnership organized under the laws of Delaware, holds 1,743,950 Shares constituting approximately 3.6% of the issued and outstanding Shares.  OrbiMed GP is the general partner of OPI VI, pursuant to the terms of the limited partnership agreement of OPI VI, and OrbiMed Advisors is the managing member of OrbiMed GP, pursuant to the terms of the limited liability company agreement of OrbiMed GP.  As a result, OrbiMed Advisors and OrbiMed GP share power to direct the vote and disposition of the Shares held by OPI VI and may be deemed directly or indirectly, including by reason of their mutual affiliation, to be the beneficial owners of the Shares held by OPI VI.  OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the Shares held by OPI VI.

     

    In addition, OrbiMed Advisors and OrbiMed GP, pursuant to their authority under the limited partnership agreement of OPI VI, caused OPI VI to enter into the agreements referred to in Item 6 below.

     

    As of the date of this filing, Worldwide Healthcare Trust PLC (“WWH”), a publicly-listed investment trust organized under the laws of England, holds 362,500 Shares constituting approximately 0.7% of the issued and outstanding Shares.  OrbiMed Capital is the investment advisor of WWH. As a result, OrbiMed Capital has the power to direct the vote and disposition of the Shares held by WWH and may be deemed directly or indirectly, including by reason of mutual affiliation, to be the beneficial owner of the Shares held by WWH.  OrbiMed Capital disclaims any beneficial ownership over the shares of the other Reporting Persons.  OrbiMed Capital exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the Shares held by WWH.

     

       

     

    As of the date of this filing, The Biotech Growth Trust PLC (“BIOG”), a publicly-listed investment trust organized under the laws of England, holds 254,877 Shares constituting approximately 0.5% of the issued and outstanding Shares.  OrbiMed Capital is the investment advisor of BIOG. As a result, OrbiMed Capital has the power to direct the vote and disposition of the Shares held by BIOG and may be deemed directly or indirectly, including by reason of mutual affiliation, to be the beneficial owner of the Shares held by BIOG.  OrbiMed Capital disclaims any beneficial ownership over the shares of the other Reporting Persons.  OrbiMed Capital exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the Shares held by BIOG.

     

    (c)

     

    Seller Date of Transaction Transaction Number of Shares Price Per Share
    BIOG 2/5/2021 Sold 3,200 $134.17
    OPI6 2/5/2021 Sold 22,200 $134.17
    WWH 2/5/2021 Sold 4,600 $134.17
    BIOG 2/8/2021 Sold 2,900 $139.37
    OPI6 2/8/2021 Sold 20,000 $139.37
    WWH 2/8/2021 Sold 4,100 $139.37
    BIOG 2/11/2021 Sold 1,500 $137.06
    OPI6 2/11/2021 Sold 9,900 $137.06
    WWH 2/11/2021 Sold 2,100 $137.06
    BIOG 2/12/2021 Sold 632 $136.11
    OPI6 2/12/2021 Sold 4,400 $136.11
    WWH 2/12/2021 Sold 900 $136.11
    BIOG 2/19/2021 Sold 5,000 $122.59
    OPI6 2/19/2021 Sold 34,100 $122.59
    WWH 2/19/2021 Sold 7,000 $122.59
    BIOG 2/22/2021 Sold 462 $122.17
    OPI6 2/22/2021 Sold 3,700 $122.17
    WWH 2/22/2021 Sold 800 $122.17
    BIOG 3/1/2021 Sold 306 $120.04
    OPI6 3/1/2021 Sold 1,800 $120.04
    WWH 3/1/2021 Sold 400 $120.04

     

     

    Except as disclosed above, the Reporting Persons have not effected any transactions during the past sixty (60) days in any Shares.

     

    (d) Not applicable.

     

       

     

    (e) As of March 1, 2021, the Reporting Persons ceased to own more than 5% of the Shares.

     

    Item 6.  Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer

     

    In addition to the relationships between the Reporting Persons described in Items 2 and 5 above, OrbiMed GP is the general partner of OPI VI, pursuant to the terms of the limited partnership agreement of OPI VI.  Pursuant to this agreement and relationship, OrbiMed GP has discretionary investment management authority with respect to the assets of OPI VI. Such authority includes the power to vote and otherwise dispose of securities held by OPI VI.  The number of outstanding Shares of the Issuer attributable to OPI VI is 1,743,950. OrbiMed GP, pursuant to its authority under the limited partnership agreement of OPI VI, may be considered to hold indirectly 1,743,950 Shares.

     

    OrbiMed Advisors is the managing member of OrbiMed GP, pursuant to the terms of the limited liability company agreement of OrbiMed GP. Pursuant to these agreements and relationships, OrbiMed Advisors and OrbiMed GP have discretionary investment management authority with respect to the assets of OPI VI.  Such authority includes the power of OrbiMed GP to vote and otherwise dispose of securities held by OPI VI.  The number of outstanding Shares attributable to OPI VI is 1,743,950 Shares.  OrbiMed Advisors, pursuant to its authority under the terms of the limited liability company agreement of OrbiMed GP, may also be considered to hold indirectly 1,743,950 Shares.

     

    OrbiMed Capital is the investment advisor to WWH and BIOG. OrbiMed Capital may be deemed to have voting and investment power over the securities held by WWH and BIOG. Such authority includes the power of OrbiMed Capital to vote and otherwise dispose of securities held by WWH and BIOG.  The number of outstanding Shares attributable to WWH is 362,500 Shares and to BIOG is 254,877 Shares.  OrbiMed Capital, as the Investment Advisor to WWH and BIOG, may also be considered to hold indirectly 617,377 Shares.

     

    Investor Rights Agreement

    In addition, OPI VI and certain other stockholders of the Issuer entered into an amended and restated investor rights with the Issuer (the “Investor Rights Agreement”), dated as of October 18, 2018. Pursuant to the Registration Rights Agreement and subject to the terms and conditions therein, the parties agreed that:

     

    Registration Rights

    Following the closing of the IPO, the holders of a certain number of Shares, or their transferees, will be entitled to the registration rights set forth below with respect to registration of the resale of such shares under the Securities Act of 1933, as amended (the “Securities Act”) pursuant to the Investors Rights Agreement.

     

    Demand Registration Rights

     

    At any time beginning or six months following the date of the underwriting agreement of the IPO, the holders of at least a majority of the registrable securities then outstanding of the Issuer may make a written request that the Issuer register some or all of their registrable securities, subject to certain specified conditions and exceptions. The Issuer is required to use commercially reasonable efforts to effect the registration and will pay all registration expenses, other than underwriting discounts and commissions, related to any demand registration. The Issuer is not obligated to effect more than two of these registrations.

     

    Piggyback Registration Rights

     

    Whenever the Issuer proposes to file a registration statement under the Securities Act, including a registration statement on Form S-3 as discussed below, other than with respect to a demand registration or a registration statement on Forms S-4 or S-8, we will be entitled to notice of the registration and have the right, subject to limitations that the underwriters may impose on the number of shares included in the registration, to include our shares in the registration.

     

       

     

    Form S-3 Registration Rights

     

    Pursuant to the Investor Rights Agreement, at any time after the Issuer is qualified to file a registration statement on Form S-3 under the Securities Act, and subject to limitations and conditions specified in the Investors Rights Agreement, a holder may make a written request that the Issuer prepare and file a registration statement on Form S-3 covering their shares, so long as the aggregate price to the public equal or exceeds $1,000,000. The Issuer is not obligated to effect more than two of these Form S-3 registrations in any 12-month period.

     

    The foregoing description of the Investor Rights Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Investor Rights Agreement, which is filed as Exhibit 2 and incorporated herein by reference.

     

     

     

     

     

     

     

     

     

     

     

       

     

    Item 7.  Material to Be Filed as Exhibits

     

     

    Exhibit Description
    1. Joint Filing Agreement among OrbiMed Advisors LLC, OrbiMed Capital LLC, and OrbiMed Capital GP VI LLC.
    2. Investor Rights Agreement by and among the Issuer and each of the persons listed on Schedule A thereto, dated as of October 18, 2018 (incorporated by reference to Exhibit 4.2 to the Issuer’s Registration Statement on Form S-1 (SEC 333-230428), filed with the SEC on March 21, 2019).

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

       

     

    Signature

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: April 7, 2021 ORBIMED ADVISORS LLC  
           
           
      By: /s/ Jonathan Silverstein  
        Name: Jonathan Silverstein  
        Title: Member  
           
      ORBIMED CAPITAL GP VI LLC  
           
      By: ORBIMED ADVISORS LLC, its managing member
           
      By: /s/ Jonathan Silverstein  
        Jonathan Silverstein  
       

    Title: Member of OrbiMed Advisors LLC

     

     
      ORBIMED CAPITAL LLC  
           
      By: /s/ Jonathan Silverstein  
        Jonathan Silverstein  
        Title: Member  

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

       

     

    SCHEDULE I

     

     

    The names and present principal occupations of each of the executive officers and directors of OrbiMed Advisors LLC are set forth below. Unless otherwise noted, each of these persons is a United States citizen and has a business address of 601 Lexington Avenue, 54th Floor, New York, NY 10022.

                 

    Name Position with Reporting Person Principal Occupation
         
         
    Carl L. Gordon Member

    Member

    OrbiMed Advisors LLC

         

    Sven H. Borho

    German and Swedish Citizen

    Member

    Member

    OrbiMed Advisors LLC

         
    Jonathan T. Silverstein Member

    Member

    OrbiMed Advisors LLC

         
    W. Carter Neild Member

    Member

    OrbiMed Advisors LLC

         
    Geoffrey C. Hsu Member

    Member

    OrbiMed Advisors LLC

         
    C. Scotland Stevens Member

    Member

    OrbiMed Advisors LLC

         
    David P. Bonita Member

    Member

    OrbiMed Advisors LLC

         
    Trey Block

    Chief Financial Officer

     

    Chief Financial Officer

    OrbiMed Advisors LLC

     

     

     

     

     

     

     

     

     

     

     

     

     

       

     

    SCHEDULE II

     

    The names and present principal occupations of each of the executive officers and directors of OrbiMed Capital LLC are set forth below. Unless otherwise noted, each of these persons is a United States citizen and has a business address of 601 Lexington Avenue, 54th Floor, New York, NY 10022.

                

    Name Position with Reporting Person Principal Occupation
         
    Carl L. Gordon Member

    Member

    OrbiMed Capital LLC

         

    Sven H. Borho

    German and Swedish Citizen

    Member

    Member

    OrbiMed Capital LLC

         
    Jonathan T. Silverstein Member

    Member

    OrbiMed Capital LLC

         
    W. Carter Neild Member

    Member

    OrbiMed Capital LLC

         
    Geoffrey C. Hsu Member

    Member

    OrbiMed Capital LLC

         
    C. Scotland Stevens Member

    Member

    OrbiMed Capital LLC

         
    David P. Bonita Member

    Member

    OrbiMed Capital LLC

         
    Trey Block

    Chief Financial Officer

     

    Chief Financial Officer

    OrbiMed Capital LLC

     

     

     

     

     

     

     

     

     

     

       

     

    SCHEDULE III 

     

    The business and operations of OrbiMed Capital GP VI LLC are managed by the executive officers and directors of its managing member, OrbiMed Advisors LLC, set forth in Schedule I attached hereto.

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

       

     

    EXHIBIT INDEX

     

     

    Exhibit Description
    1. Joint Filing Agreement among OrbiMed Advisors LLC, OrbiMed Capital LLC, and OrbiMed Capital GP VI LLC.
    2. Investor Rights Agreement by and among the Issuer and each of the persons listed on Schedule A thereto, dated as of October 18, 2018 (incorporated by reference to Exhibit 4.2 to the Issuer’s Registration Statement on Form S-1 (SEC 333-230428), filed with the SEC on March 21, 2019).

     

     

     

     

     

     

     

     

     

     

     

     

       
    Get the next $TPTX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $TPTX

    DatePrice TargetRatingAnalyst
    5/20/2022$58.00Buy
    BofA Securities
    3/1/2022$50.00 → $45.00Hold
    Stifel
    2/10/2022$120.00 → $85.00Overweight
    Wells Fargo
    1/21/2022$115.00 → $105.00Outperform
    Oppenheimer
    12/7/2021Outperform
    Cowen & Co.
    11/10/2021$150.00 → $115.00Outperform
    Oppenheimer
    10/12/2021$178.00 → $162.00Buy
    HC Wainwright & Co.
    10/11/2021Market Outperform → Market Perform
    JMP Securities
    More analyst ratings

    $TPTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Turning Point Therapeutics Inc.

      SC 13G - Turning Point Therapeutics, Inc. (0001595893) (Subject)

      2/14/22 3:02:35 PM ET
      $TPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Turning Point Therapeutics Inc. (Amendment)

      SC 13G/A - Turning Point Therapeutics, Inc. (0001595893) (Subject)

      2/14/22 2:35:02 PM ET
      $TPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Turning Point Therapeutics Inc. (Amendment)

      SC 13G/A - Turning Point Therapeutics, Inc. (0001595893) (Subject)

      2/9/22 10:01:27 AM ET
      $TPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TPTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Nicholson Garry A (tax withholding)

      4 - Turning Point Therapeutics, Inc. (0001595893) (Issuer)

      8/17/22 4:43:52 PM ET
      $TPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Machado Patrick (withholding obligation)

      4 - Turning Point Therapeutics, Inc. (0001595893) (Issuer)

      8/17/22 4:41:51 PM ET
      $TPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4: George Simeon returned $171,278,160 worth of shares to the company (2,253,660 units at $76.00) to cover taxes

      4 - Turning Point Therapeutics, Inc. (0001595893) (Issuer)

      8/17/22 4:40:00 PM ET
      $TPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TPTX
    Leadership Updates

    Live Leadership Updates

    See more

    $TPTX
    SEC Filings

    See more

    $TPTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • NorthStar Medical Technologies, LLC Announces Appointment of Barbara Bodem and David Keeling to Board of Managers

      NorthStar Medical Technologies, LLC, parent company of NorthStar Medical Radioisotopes, LLC, a global innovator in development, production and commercialization of radiopharmaceuticals used to detect and treat cancer and other serious diseases, today announced the appointment of Barbara W. Bodem and David Keeling to its Board of Managers, effective February 12, 2024. Following these appointments, the Board will comprise of 8 directors, 5 of whom are non-executive. "We are pleased to welcome Barbara and David to the NorthStar Board," said Stephen Merrick, Executive Chairman of NorthStar. "Barbara's deep experience serving in senior finance and board roles in leading edge pharmaceutical and

      2/27/24 9:00:00 AM ET
      $BMRN
      $ENOV
      $OPCH
      $SYNH
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Industrial Specialties
      Medical/Nursing Services
    • Turning Point Therapeutics Announces Appointment of Steve Sabus as Chief Commercial Officer

      SAN DIEGO, May 16, 2022 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ:TPTX), a clinical-stage precision oncology company designing and developing novel targeted therapies for cancer treatment, today announced the appointment of Steve Sabus as Chief Commercial Officer, effective as of May 31, 2022. Prior to Turning Point, Mr. Sabus spent 15 years in roles with increasing levels of sales responsibility at Astellas Pharma, most recently serving as the Head of Oncology leading a group of over 300 team members. In this role he provided executive leadership to scale the company's $3 billion U.S. oncology franchise by launching and growing new products. His achievements include su

      5/16/22 8:30:00 AM ET
      $TPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Turning Point Therapeutics Announces Appointment of Brian Sun, M.S., J.D., as Incoming General Counsel

      SAN DIEGO, March 29, 2022 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ:TPTX), a clinical-stage precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced the appointment of Brian Sun, M.S., J.D. as its incoming Senior Vice President and General Counsel, effective as of April 11, 2022. Mr. Sun currently serves as Senior Vice President and General Counsel at Sorrento Therapeutics, Inc, a Nasdaq-listed company, where he leads the legal function and team. Previously, he worked at Prometheus Laboratories and Hologic and served as outside general counsel to early-stage biotechnology companies. Earlier in his career, Mr

      3/29/22 9:00:00 AM ET
      $TPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 15-12G filed by Turning Point Therapeutics Inc.

      15-12G - Turning Point Therapeutics, Inc. (0001595893) (Filer)

      8/29/22 4:30:18 PM ET
      $TPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Turning Point Therapeutics Inc.

      EFFECT - Turning Point Therapeutics, Inc. (0001595893) (Filer)

      8/23/22 12:15:10 AM ET
      $TPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-8 POS filed by Turning Point Therapeutics Inc.

      S-8 POS - Turning Point Therapeutics, Inc. (0001595893) (Filer)

      8/17/22 9:02:25 AM ET
      $TPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BofA Securities initiated coverage on Turning Point Therapeutics with a new price target

      BofA Securities initiated coverage of Turning Point Therapeutics with a rating of Buy and set a new price target of $58.00

      5/20/22 7:27:32 AM ET
      $TPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Stifel reiterated coverage on Turning Point with a new price target

      Stifel reiterated coverage of Turning Point with a rating of Hold and set a new price target of $45.00 from $50.00 previously

      3/1/22 11:13:37 AM ET
      $TPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wells Fargo reiterated coverage on Turning Point with a new price target

      Wells Fargo reiterated coverage of Turning Point with a rating of Overweight and set a new price target of $85.00 from $120.00 previously

      2/10/22 7:06:48 AM ET
      $TPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TPTX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Axonis Therapeutics Announces $115 Million Series A Financing

      -- Oversubscribed financing brings together leading syndicate of life sciences investors -- -- Proceeds to support clinical development of first-in-class therapies for neurological disorders – BOSTON, Oct. 30, 2024 /PRNewswire/ -- Axonis Therapeutics, a biotechnology company focused on the development of novel neuromedicines, announced today the successful completion of an oversubscribed $115 million Series A financing. Proceeds from the financing will be used to advance Axonis' lead development candidate, AXN-027, through clinical proof-of-concept in patients. AXN-027 is a first-in-class oral small molecule designed to potentiate the function of KCC2, a major CNS chloride transporter essent

      10/30/24 6:00:00 AM ET
      $AKRO
      $APLS
      $AUPH
      $HRMY
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Specialty Chemicals
      Consumer Durables
    • venBio Raises $528 Million Venture Capital Fund Focused on Life Science Companies

      - venBio promotes Yvonne Yamanaka, Ph.D. to Partner venBio today announced the closing of venBio Global Strategic Fund V ("venBio Fund V"), its fifth life sciences venture capital fund, exceeding its target and closing on approximately $528 million in capital commitments in an oversubscribed fundraise. The firm initiated the fundraise for Fund V in mid-April. Limited partners of Fund V include a broad range of institutional investors comprising sovereign wealth funds, corporate pensions, financial institutions, university endowments, medical institutions, foundations, family offices and funds-of-funds. Under the fund leadership of Managing Partners Richard Gaster, M.D., Ph.D., Corey Goo

      8/1/24 8:00:00 AM ET
      $AKRO
      $APLS
      $AUPH
      $HRMY
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Specialty Chemicals
      Consumer Durables
    • NorthStar Medical Technologies, LLC Announces Appointment of Barbara Bodem and David Keeling to Board of Managers

      NorthStar Medical Technologies, LLC, parent company of NorthStar Medical Radioisotopes, LLC, a global innovator in development, production and commercialization of radiopharmaceuticals used to detect and treat cancer and other serious diseases, today announced the appointment of Barbara W. Bodem and David Keeling to its Board of Managers, effective February 12, 2024. Following these appointments, the Board will comprise of 8 directors, 5 of whom are non-executive. "We are pleased to welcome Barbara and David to the NorthStar Board," said Stephen Merrick, Executive Chairman of NorthStar. "Barbara's deep experience serving in senior finance and board roles in leading edge pharmaceutical and

      2/27/24 9:00:00 AM ET
      $BMRN
      $ENOV
      $OPCH
      $SYNH
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Industrial Specialties
      Medical/Nursing Services

    $TPTX
    Financials

    Live finance-specific insights

    See more
    • Bristol Myers Squibb Reports Second Quarter Financial Results for 2022

      Reports Second Quarter Revenues of $11.9 Billion, an Increase of 2% YoY; or 5% When Adjusted for Foreign Exchange Posts Second Quarter Earnings Per Share of $0.66 and Non-GAAP EPS of $1.93; Includes Net Impact of ($0.14) per share for GAAP and Non-GAAP EPS Due to Acquired IPRD1 Charges and Licensing Income Delivers Robust Revenue Growth of 11% from In-Line Products and New Product Portfolio; or 16% When Adjusted for Foreign Exchange Expands Oncology Franchise with New Indications for Opdivo and Planned Acquisition of Precision Oncology Company, Turning Point Therapeutics Strengthens Cell Therapy Franchise with Broadest Label for Breyanzi in Relapsed or Refractory Large B-cell Lymph

      7/27/22 6:59:00 AM ET
      $BMY
      $IMTX
      $TPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Turning Point Therapeutics Announces Pipeline Expansion, Licensing of TPX-4589 (LM-302), A Clinical Stage Anti-Claudin18.2 Antibody Drug Conjugate for Gastrointestinal Cancers, From Lanova Medicines

      Strategic Expansion of Turning Point Precision Oncology Portfolio TPX-4589 (LM-302) Currently in Two Ongoing Phase 1 Studies Agreement Includes Potential Broader Scope to Collaborate on up to Three Additional ADC Programs SAN DIEGO, May 05, 2022 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ:TPTX), a clinical-stage precision oncology company designing and developing novel targeted therapies for cancer treatment, announced today that it has entered into an exclusive license agreement with LaNova Medicines Limited (LaNova) to develop and commercialize LM-302, a novel antibody drug conjugate (ADC) targeting Claudin18.2, in the U.S. and rest of the world, excluding Greater Chi

      5/5/22 9:00:00 AM ET
      $TPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Turning Point Therapeutics Announces Positive Topline Data by Blinded Independent Central Review for Repotrectinib Across All ROS1-Positive NSCLC Cohorts of Phase 1/2 TRIDENT-1 Study

      In a total of 71 TKI-naïve patients, confirmed objective response rate (cORR) of 79% (95% CI: 68, 88)In the TKI-naïve population with approximately 10 months of follow-up, initial estimated durability of response and progression free survival of 85% and 82% at 12-month landmarks, respectivelyIn TKI-pretreated patients, cORR of 42% in those treated with 1 TKI and platinum-based chemotherapy (EXP-2), cORR of 28% in those treated with two TKIs (EXP-3), and cORR of 36% in those treated with 1 TKI (EXP-4) In TKI-pretreated patients with an identified ROS1 G2032R solvent front mutation, cORR of 59%Pre-NDA meeting anticipated this quarter to discuss potential NDA in ROS1-positive NSCLC Conference C

      4/12/22 4:46:10 PM ET
      $TPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care